stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.51
1.98
+6.09%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Gross margin
Pharvaris N.V.'s gross margin over the twelve months to 30 September 2023 was 0.00%, down 0.0 percentage points from fiscal 2022 (0.00%). That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| 4 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | 100.0% |
| VCEL Vericel Corporation compare | 74.5% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 29.2% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PHVS Pharvaris N.V. | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue